TY  - GEN
AB  - Acute myeloid leukemia (AML) is the most common leukemia in adults and is primarily diagnosed in older patients. The combination of the BCL2 inhibitor, venetoclax, with a hypomethylating agent has recently become standard of care front-line therapy for patients who are unfit for high intensity induction chemotherapy and allogeneic stem cell transplantation. However, for patients who experience disease refractoriness/relapse, second line treatment options are limited. Natural killer (NK) cells have been shown to have potent anti-tumor effects in AML may represent a potential therapeutic option for patients with progression after venetoclax-based therapy.
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AU  - Chandra, Daniel
AU  - Burns, Faith
AU  - Kosaka, Yoko
AU  - Kurtz, Stephen E.
AU  - Tyner, Jeffrey W.
AU  - Lind, Evan F.
AU  - Saultz, Jennifer N.
DA  - 2024
DO  - 10.6083/bpxhc43584
DO  - doi
ID  - 43584
KW  - Induction Chemotherapy
KW  - Standard of Care
KW  - Leukemia, Myeloid, Acute
KW  - Killer Cells, Natural
KW  - Interferons
KW  - Hematopoietic Stem Cell Transplantation
KW  - venetoclax
KW  - HLA-E antigens
KW  - ruxolitinib
L1  - https://digitalcollections.ohsu.edu/record/43584/files/ResearchWeek.2024.Chandra.Daniel.pdf
L2  - https://digitalcollections.ohsu.edu/record/43584/files/ResearchWeek.2024.Chandra.Daniel.pdf
L4  - https://digitalcollections.ohsu.edu/record/43584/files/ResearchWeek.2024.Chandra.Daniel.pdf
LA  - eng
LK  - https://digitalcollections.ohsu.edu/record/43584/files/ResearchWeek.2024.Chandra.Daniel.pdf
N2  - Acute myeloid leukemia (AML) is the most common leukemia in adults and is primarily diagnosed in older patients. The combination of the BCL2 inhibitor, venetoclax, with a hypomethylating agent has recently become standard of care front-line therapy for patients who are unfit for high intensity induction chemotherapy and allogeneic stem cell transplantation. However, for patients who experience disease refractoriness/relapse, second line treatment options are limited. Natural killer (NK) cells have been shown to have potent anti-tumor effects in AML may represent a potential therapeutic option for patients with progression after venetoclax-based therapy.
PB  - Oregon Health and Science University
PY  - 2024
T1  - Upregulation of HLA-e drives defective natural killer cell targeting in venetoclax-resistant acute myeloid leukemia
TI  - Upregulation of HLA-e drives defective natural killer cell targeting in venetoclax-resistant acute myeloid leukemia
UR  - https://digitalcollections.ohsu.edu/record/43584/files/ResearchWeek.2024.Chandra.Daniel.pdf
Y1  - 2024
ER  -